AM251
 | |
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | 183232-66-8 |
| PubChem (CID) | 2125 |
| IUPHAR/BPS | 3317 |
| ChemSpider |
2040  Y |
| ChEBI |
CHEBI:90724 Y |
| ChEMBL |
CHEMBL285932 Y |
| Chemical and physical data | |
| Formula | C22H21Cl2IN4O |
| Molar mass | 555.238 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
AM-251 is an inverse agonist at the CB1 cannabinoid receptor. AM-251 is structurally very close to SR141716A (rimonabant); both are biarylpyrazole cannabinoid receptor antagonists. In AM-251 the p-chloro group attached to the phenyl substituent at C-5 of the pyrazole ring is replaced with a p-iodo group. The resulting compound exhibits slightly better binding affinity for the CB1 receptor (with a Ki value of 7.5nM) than SR141716A, which has a Ki value of 11.5nM, AM-251 is, however, about two-fold more selective for the CB1 receptor when compared to SR141716A.[1] Like SR141716A, it is additionally a μ-opioid receptor antagonist.[2]
See also
References
- ↑ Lan, R., Liu, Q., Fan, P., et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42 769-776 (1999). PubMed 10052983
- ↑ AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct;63(5):905-15. doi: 10.1016/j.neuropharm.2012.06.046. Epub 2012 Jul 4. PMID 22771770 PMCID: PMC3408547
| Receptor (ligands) |
| ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) |
| ||||||||||||||||||
| Enzyme (modulators) |
| ||||||||||||||||||
| Others |
| ||||||||||||||||||
| |||||||||||||||||||
| MOR |
|
|---|---|
| DOR |
|
| KOR |
|
| NOP |
|
| Unsorted |
|
| Others |
|
See also: Peptide receptor modulators | |
This article is issued from Wikipedia - version of the 6/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.